viewSynairgen PLC

Synairgen believes interferon beta candidate has potential

The company, which developed and out-licensed AZD9412, believes the interferon beta candidate has potential.

Synairgen will take a close look at the data before deciding in which direction it will go

AstraZeneca PLC (LON:AZN) has returned the rights to a promising respiratory drug for ‘strategic reasons’, according to an update from pharma giant.

Synairgen plc (LON:SNG), which developed and out-licensed AZD9412, believes the interferon beta candidate has potential.

Based on the biomarker, lung function and safety data, it may be developed to treat lung diseases where viral infections are a real problem, such as chronic obstructive pulmonary disease (COPD).

CLICK HERE: For a daily round-up of all the Proactive news

First, Synairgen wants to see the data from the AZ study of asthma patients.

"We remain positive about the potential of inhaled interferon beta, particularly for patients with COPD who suffer due to respiratory viruses,” said chief executive Richard Marsden.

“Once we have completed the data analysis, we will provide an update on the programme and our plans for future development." 

Looking ahead, the company will complete toxicology studies on its LOXL2 candidate, designed to reduce fibrosis in patients with idiopathic pulmonary fibrosis, and plans to take it into a phase I clinical trial later this year.

Quick facts: Synairgen PLC

Price: 46 GBX

Market: AIM
Market Cap: £68.74 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...



Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read